Panelists discuss the challenges of implementing susceptibility testing for new antibiotics, emphasizing the need for close lab-clinician collaboration, streamlined reflex testing protocols, and investment in diagnostic infrastructure to ensure timely and effective treatment of multidrug-resistant infections.
Panelists discuss the evolving landscape of novel antibiotic combinations targeting metallo-β-lactamase (MBL)–producing and other multidrug-resistant Gram-negative bacteria, emphasizing promising early data despite limited clinical trials, the complexity of resistance mechanisms, and the potential for these therapies to improve outcomes and shape future treatment strategies.
Panelists discuss the innovative use of the aztreonam-avibactam combination to combat complex β-lactamase–mediated resistance, highlighting promising laboratory data, challenges in clinical trial enrollment for resistant infections, and the ongoing need for further research to define its role in treating multidrug-resistant Gram-negative pathogens.
Panelists discuss the real-world challenges of managing infections caused by highly resistant organisms, highlighting the impact of limited access to novel diagnostics and therapeutics, the complexities of outpatient treatment, and the urgent need for broader-spectrum agents and improved delivery methods in resource-constrained settings.
Jennifer Le, PharmD, MAS, FIDSA, FCCP, FCSHP, discusses her collaboration on this innovative work with this therapy in severely ill children.
Episode 2, Part 4, Robert Bransfield, MD, connects neural circuits, inflammatory responses to infection, and impulsivity in violent behavior.
Part 2 on coverage across payers, evidence needs for COVID-19, hepatitis B, and MMRV, and clinician messaging for maternal and newborn protection.
In our continuing conversation with Victor Nizet, MD, he discusses how his laboratory is studying how to repurpose antibiotics that susceptibility testing had shown to not be efficacious against certain infections.
In part 1 of our conversation, the VP of the NFID discusses ACIP’s recent meeting, including COVID-19 shared decision-making, informed-consent debates, and new policy actions on hepatitis B and MMRV.
Pranita Tamma, MD, MHS, discusses recent studies comparing ceftolozane-tazobactam and ceftazidime-avibactam for drug-resistant Pseudomonas infections, emphasizing similar mortality outcomes, high rates of emerging resistance, and the importance of stewardship practices that prioritize preserving ceftazidime-avibactam for broader clinical use.
Victor Nizet, MD, discusses how students can thrive at the university’s Skaggs School of Pharmacy and Pharmaceutical Sciences. He discusses the school's features including its rigorous coursework, focus on research, and community-based health care opportunities.
Panelists discuss the critical need for a coordinated, multidisciplinary approach to managing infections caused by metallo-β-lactamase (MBL)–producing organisms, emphasizing early identification, containment, careful selection of limited therapeutic options, and stewardship-guided use of novel agents to preserve their long-term effectiveness.
Panelists discuss practical strategies for empiric antibiotic selection in the face of rising multidrug resistance, stressing the importance of infection confirmation, patient risk assessment, local resistance data, and stewardship-guided use of newer agents to ensure appropriate and sustainable treatment decisions.
Ryan Shields, PharmD, MS, discusses the challenges of incorporating newer antibiotics for gram-negative infections, how he is using broad-spectrum antimicrobial agents for these infections, and the factors he looks for in considering new agents.
Monica V. Mahoney, PharmD, BCPS, BCIDP, FCCP, FIDSA, FIDP, FMSHP, provides insights on the outpatient side of therapy, including treating outpatients for gram-negative infections.
Rodney E. Rohde, PhD, SV/SM/MB(ASCP)CM, FACSc, offers some insights on the latest diagnostics, susceptibility testing for newer antimicrobials, and how infectious disease clinicians and laboratory professionals can collaborate on challenging cases.
Panelists discuss the pivotal role of microbiology laboratories and rapid diagnostic technologies in managing multidrug-resistant infections, highlighting their impact on timely treatment, antibiotic stewardship, and the need for interdisciplinary collaboration to effectively interpret and act on resistance data.
Panelists discuss emerging therapies for multidrug-resistant Gram-negative pathogens, focusing on the rising threat of antimicrobial resistance, evolving resistance mechanisms like extended-spectrum β-lactamases (ESBLs) and New Delhi metallo-β-lactamases (NDMs), regional variability in pathogen prevalence, and the clinical implications for treatment in inpatient and outpatient settings.
Jacinda Abdul-Mutakabbir, PharmD, MPH, provides insights on her recently published study on this topic and how the 2 are connected.
Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses how an analysis of infection source and treatment patterns found no evidence that combination therapy improves outcomes in patients with drug-resistant Pseudomonas, consistent with prior studies and clinical trials.
In the second interview segment with leaders from UNC's Special Pathogen Center, they discuss what it is like to be in the field during an outbreak caring for patients with high-consequence infectious diseases, and offer insights on how well prepared the US is for these situations.
David Margolis, MD discusses his team’s work at UNC looking at combination treatment that includes the cancer drug, vorinostat, and immunotherapy as a potential HIV cure.
This becomes the first state in the United States to do so, and of course, this decision will affect the childhood vaccine schedule in Florida. Infectious Diseases Society of America (IDSA) President, Tina Tan, MD, weighs in on this decision and what this could mean for an increase of vaccine-preventable diseases and who would be vulnerable to them.
Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses how clinicians can help reduce the emergence of antimicrobial resistance by using higher doses with extended infusions, limiting treatment duration, ensuring source control, and avoiding unnecessary dose reductions during CRRT.
Joseph Eron, MD, provides insights on the unit's international reach as well as some of the important trials it has been involved in, notably the PURPOSE studies involving the landmark trials about lenacapavir for HIV prevention.
Leaders from the UNC Special Pathogens Response Center discuss how they plan and carry out biopreparedness trainings to address transport and care of patients with high-consequence infectious diseases, such as Ebola or Lassa fever.
Allergist and immunologist Juanita Mora, MD, urges vaccination, masking, and outreach to safeguard vulnerable communities.
In the second episode of Allegheny Health Network’s (AHN) Media Day, Cassandra Oehler, MD, provides insights on HIV care at AHN's Positive Health Clinic (PHC), including the comprehensive services they offer and how they are involved in clinical trials using long-acting injectables.
Pranita Tamma, MD, MHS, continues her conversation about a study she was involved in that compared ceftolozane-tazobactam and ceftazidime-avibactam. She discusses the usage of inverse probability weighting with propensity scores to balance patient groups and limit bias.
As virus season begins, Leilani Valdes, MD, MBA, FCAP, highlights the lab’s role in early detection and the importance of informed, respectful dialogue on vaccines.
